Doramapimod (BIRB 796)

Catalog No.S1574

For research use only.

Doramapimod (BIRB 796) is a pan-p38 MAPK inhibitor with IC50 of 38 nM, 65 nM, 200 nM and 520 nM for p38α/β/γ/δ in cell-free assays, and binds p38α with Kd of 0.1 nM in THP-1 cells, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2.

Doramapimod (BIRB 796) Chemical Structure

CAS No. 285983-48-4

Selleck's Doramapimod (BIRB 796) has been cited by 99 publications

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Other p38 MAPK Products

Biological Activity

Description Doramapimod (BIRB 796) is a pan-p38 MAPK inhibitor with IC50 of 38 nM, 65 nM, 200 nM and 520 nM for p38α/β/γ/δ in cell-free assays, and binds p38α with Kd of 0.1 nM in THP-1 cells, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2.
Features The first p38 MAPK inhibitor to be tested in a phase III clinical trial.
Targets
JNK2 [1] c-RAF [1] Fyn [1] p38α [1]
(Cell-free assay)
p38α [7]
0.1 nM(Kd) 38 nM
In vitro

BIRB 796 shows no significant inhibition to ERK-1, SYK, IKK2β, ZAP-70, EGF receptor kinase, HER2, protein kinase A (PKA), PKC, PKC-α, PKC-β (I and II) and PKC-γ. BIRB 796 greatly improves binding affinity by forming a hydrogen bond between the morpholine oxygen and the ATP-binding domain of p38α. BIRB 796 represents one of the most potent and slowest dissociating inhibitors against human p38 MAP kinase now known. [1] BIRB 796 potently inhibits c-Raf-1 and Jnk2α2 with IC50 of 1.4 and 0.1 nM, respectively. [2] BIRB796 also inhibits the activity and the activation of SAPK3/p38γ at a higher concentration than it does in p38α. BIRB796 blocks the stress-induced phosphorylation of the scaffold protein SAP97, which is a physiological substrate of SAPK3/p38γ. BIRB796 blocks JNK1/2 activation and activity in HEK293 cells, while not inhibits the activation and activity of ERK1/ERK2 in Hela cells. Moreover, the binding of BIRB796 to the p38 MAPKs or JNK1/2 is impairing their phosphorylation by the upstream kinase MKK6 or MKK4 rather than enhancing their dephosphorylation. [3] BIRB 796 blocks baseline and bortezomib-triggered upregulation of p38 MAPK and Hsp27 phosphorylation, thereby enhancing cytotoxicity and caspase activation. BIRB 796 downregulates IL-6 and VEGF secretion in BMSCs triggered by TNF-α and TGF-β1. [4] BIRB-796 has a pyrazole scaffold that places a lipophilic t-butyl group into the lower selectivity site and a tolyl ring into the upper selectivity site. BIRB-796 also inhibits B-Raf and Abl with IC50 of 83 nM and 14.6 μM, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HOP-92 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj4TWM2OD1{ND6zPFM5KM7:TR?= MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
NCI-H2228 NE\qU4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\zRWlEPTB;MkOuOlY3QCEQvF2= NYrQSY1iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
CAPAN-1 M3\3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrlTWM2OD1{Mj6xPFg1KM7:TR?= NYD3TGNERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
SK-MEL-1 NWnsbWtJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnrWFhKSzVyPUKwMlM3QDNizszN M3WyOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
DB Mmf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2izbGlEPTB;MUiuO|kzOyEQvF2= Mo\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
AN3-CA Mn\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPpTId7UUN3ME2xPE4yKM7:TR?= NEPxb3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
EW-13 NIfwWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnMUIJCUUN3ME2xO{46PTF4IN88US=> M4TxcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
LC-2-ad NHTNUlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTF5LkSzOlYh|ryP MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
ES8 NWLXTm5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnrSndyUUN3ME2xO{4yPjdizszN M1e2UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
NCI-H1581 MoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmSwTWM2OD1zNz6wOFQ4KM7:TR?= NHi1WJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
HMV-II MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fPZ2lEPTB;MUSuNlMxQSEQvF2= NITYeIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
BEN MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T0dWlEPTB;MUOuNVI3PCEQvF2= NFf5b3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
NBsusSR MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTFyLkiyN|Uh|ryP M3HuN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
MS-1 M2\4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTFyLkiyN|Uh|ryP MoHsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
BFTC-905 MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTFyLkGyN|Mh|ryP NX;QZnh3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
NCI-SNU-1 Mnj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:5VmlEPTB;OT6wOlc{QSEQvF2= NUnZPYtGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
MPP-89 NHXMU2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRThwNE[yOVEh|ryP NFL2WW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
T-24 Mn;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXQTWM2OD16LkSwOlc{KM7:TR?= NWfTUnNCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
KP-N-YN M4\GNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXDS5g5UUN3ME24MlIxOTlizszN M1npSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
IST-MES1 NEfsc4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4KybmlEPTB;Nz65OVY{PyEQvF2= NGfHT|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
NCI-H358 MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfSSpBoUUN3ME23MlU{QCEQvF2= MlKxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
GOTO Mmn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DKVmlEPTB;Nj6zPVE3OSEQvF2= MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
DU-145 M4jsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LoVmlEPTB;Mz65N|gyOSEQvF2= M2f4OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
EoL-1-cell NWDRfXd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[zW4lzUUN3ME2wMlM1PzZ|IN88US=> MlTCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
KYSE-270 M{jNbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfhPIdKSzVyPUK0MlU2PzNizszN NV;NcpFKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
HCC1806 MkK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPrTWM2OD1{ND63O|k6KM7:TR?= NXvVS5JPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
HuO-3N1 NVG1WFdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTJ3LkixPFUh|ryP MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
HOS MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTJ3LkmyPVIh|ryP M1q2dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
KYSE-510 NED6PWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4ix[WlEPTB;Mk[uNVYyOiEQvF2= M13vZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
COLO-741 NHjIb4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHkS5VKSzVyPUK2MlM{OjlizszN MlnyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
H-EMC-SS M37Ke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLKTWM2OD1{Nj65NlQ2KM7:TR?= MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
HCC1937 NVHJcFZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJ5LkKyN|gh|ryP NIDydIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
NCI-H2126 NIm1b5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvwdGpFUUN3ME2yO{4{QTd3IN88US=> NUH5N4dbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
NCI-H1703 NX7vNFFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnRTYpKSzVyPUK4MlA1OTNizszN M{XqdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
U-2-OS MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHmTWM2OD1{OD61OVE2KM7:TR?= MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
DBTRG-05MG MnTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LWWGlEPTB;MkiuOVY2OSEQvF2= MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
MHH-ES-1 M4jtSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYT4cGFHUUN3ME2zNU46PDFizszN Mo\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
HCC1419 NGi2[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\PeHNJUUN3ME2zNk4yOTF7IN88US=> NV7pcHI{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
HOP-62 NGHLPIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M123TGlEPTB;M{KuNlcxOSEQvF2= Mn;NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
AM-38 MmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET5fWNKSzVyPUOyMlk6OzFizszN NELvSYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
NCI-H2009 Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLQeo5KSzVyPUOzMlQxODdizszN NGfsSmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
EM-2 M{jMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTN|LkW1NVEh|ryP M37SN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
SW1116 NGfLRXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHRTWM2OD1|ND60PFM5KM7:TR?= M{DQOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
SK-N-AS M3XSNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfzdplKSzVyPUO1MlA4OTRizszN M1PYeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
ChaGo-K-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\ITWM2OD1|NT62NFMzKM7:TR?= MoftQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
RT-112 NUPCVGZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjNRodqUUN3ME2zOU46QDd7IN88US=> MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNFM3PjdxJ{7TRW5ITVJ:L3G+
HTC-C3 NH\VempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDxWXFKSzVyPUO2MlI{PTVizszN NW\aSIh5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
SK-NEP-1 MoiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfsfHZKSzVyPUO2MlYyODZizszN M17rOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
LB831-BLC MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnyVVNKSzVyPUO3MlY2PDFizszN NV3nPZhHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
CTB-1 Mn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTN6LkS1NVIh|ryP MmTCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
MOLT-4 NVfHWFY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTN6LkizPVEh|ryP MmS3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVA{PjZ5Lze+V2FPT0WUPD;hQi=>
SW756 M2PmZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFr4cJpKSzVyPUSwMlk{QDVizszN NVi3[JcyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
CAL-72 NYDNeXFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;UcGlEPTB;NEKuNFMh|ryP NIDrTpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
KNS-62 MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\vV5pvUUN3ME20Nk43Ojl4IN88US=> NWXsNI9DRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
KARPAS-299 MlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmW4TWM2OD12Mz6zNlM{KM7:TR?= M4\3ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
HEL MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTR3LkS2OFYh|ryP NEH4bXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyODN4NkevK|5USU6JRWK8M4E,
KP-4 NXXLXmtlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\UTWM2OD12Nj63N|YyKM7:TR?= NYLJemJ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
NEC8 NU\sb4V4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jCbGlEPTB;NEeuNVY3OSEQvF2= M1HBTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFExOzZ4Nz:nQnNCVkeHUkyvZV4>
G-402 M4PROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTR6LkewNVIh|ryP NVHtSG5yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTB|Nk[3M{c,W0GQR1XSQE9iRg>?
Sf21 NHf2[ZlHfW6ldHnvckBie3OjeR?= MXXCbY5lcW6pIHHm[olvcXS7IITvJJdqdGRidInw[UBpfW2jbjDibY91cW5ibHHi[Yxt\WRicEO4JIFteGijIDi5JJRwKDN3MjDy[ZNq\HWnczmg[ZhxemW|c3XkJIlvKHOoMkGgbY5{\WO2IHPlcIx{KFOSUjDhcoFtgXOrczygT4QhRSByLkCwNFEzOyEQvF2u MofrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6M{S0N|EoRjJ6OEO0OFMyRC:jPh?=
THP1 M1;kfmZ2dmO2aX;uJIF{e2G7 NGixb29KdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJHRPTmGucHjhJJBzd2S3Y4Tpc44hcW5iaIXtZY4hXEiSMTDj[YxteyxiSVO1NEA:KDBwMEGzJO69VS5? NGG2XnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOyOVc3QCd-MUizNlU4Pjh:L3G+
U937 MXTBcpRqcW6obHHtcYF1d3K7IHHzd4F6 M1WwVlIhcHK| MYjBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHnuJIRq\m[ncnXueIlifGWmIHj1cYFvKFV7M{egZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCOUGOtbY5lfWOnZDDUUmZidHCqYTDwdo9lfWO2aX;uJJBz\WmwY4XiZZRm\CCob4KgNkBpenNiZn;scI94\WRiYomgUHBUNXO2aX31cIF1cW:wIH\vdkA1KGi{czDifUB{[W6md3njbEBGVEmVQTDy[YxifGm4ZTD0c{B3\WirY3zlMZRz\WG2ZXSgZ49vfHKxbDygTWM2OCB;IECuNFE2KM7:TT6= NWjkPGtRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4NFA{ODlpPkK2PFAxOzB7PD;hQi=>
THP1 NUn6SJpJTnWwY4Tpc44h[XO|YYm= MXjJcohq[mm2aX;uJI9nKEySUz3pcoR2[2WmIGTOSoFteGijIIDyc4R2[3Srb36gbY4hcHWvYX6gWGhROSClZXzsd{whUUN3MDC9JFAvODF6IN88UU4> M1\zWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{W2PVI6Lz5zOUO1OlkzQTxxYU6=
THP1 M3jFTWZ2dmO2aX;uJIF{e2G7 NXvxcnlOUW6qaXLpeIlwdiCxZjDMVHMucW6mdXPl[EB1fW2xcjDu[YNzd3OrczDmZYN1d3JvYXzwbIEhMFSQRj3hcJBp[SlicILv[JVkfGmxbjDpckBVUFBvMTDj[YxteyxiRVO1NEA:KDBwMEG4JO69VS5? MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjB6NkS4OUc,OTJyOE[0PFU9N2F-
THP MXrGeY5kfGmxbjDhd5NigQ>? NWrncYVlXGW|dHXkJIZweiCrbnjpZol1cW:wIH;mJHR2dW:{IH7lZ5Jwe2m|IH\hZ5RweixiYXzwbIEhcW5iVFjQJINmdGy|LDDFR|UxKD1iMD6wNVgh|ryPLh?= NEXNTXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNEW2NVA5Pyd-MUS1OlExQDd:L3G+
THP1 MUjGeY5kfGmxbjDhd5NigQ>? M2rSVGlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgWG5H[WyyaHGgdJJw\HWldHnvckBqdiCWSGCxJINmdGy|LDDJR|UxKD1iMD6wNVgh|ryPLh?= NYfLOIFIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OlAyODhpPkG3OVYxOTB6PD;hQi=>
THP1 MofxSpVv[3Srb36gZZN{[Xl? NVGyWHlWUW6qaXLpeIlwdiCxZjDMVHMue3SrbYXsZZRm\CCWTl\hcJBp[SCycn;keYN1cW:wIHnuJIh2dWGwIGTIVFEh[2WubIOsJGlEPTBiPTCwMlAyQCEQvF2u MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR4Mkm0NEc,OTh2NkK5OFA9N2F-
HLF NUS1eVdxTnWwY4Tpc44h[XO|YYm= MmH5TY5pcWKrdHnvckBw\iCyM{jhcJBp[SCyaH;zdIhwenmuYYTpc44hcW5iSVytNU1idHCqYT3zeIlufWyjdHXkJGhNTiClZXzsd{whUUN3MDC9JFAvODR5IN88UU4> MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZyMkK2Nkc,OTh4MEKyOlI9N2F-
HLF M2DsTGZ2dmO2aX;uJIF{e2G7 MX;Jcohq[mm2aX;uJI9nKEiVUEK3JJBpd3OyaH;yfYxifGmxbjDpckBKVC1zLXHsdIhiNXO2aX31cIF1\WRiSFzGJINmdGy|LDDJR|UxKD1iMD6wOVgh|ryPLh?= MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZyMkK2Nkc,OTh4MEKyOlI9N2F-
HEK293F M3TnZ2Z2dmO2aX;uJIF{e2G7 NUnXb4FLUW6qaXLpeIlwdiCxZjDzc4RqfW1iYYLz[Y5ifGViYXP0bZZifGWmIF6teIVzdWmwYXygS3NVNXSjZ3fl[EBDenWpaXGgcYFt[XmrIF3QT|Eh\XiycnXzd4VlKGmwIFjFT|I6O0ZiY3XscJMhfXOrbnegSmFONXB|OITp[IUh[XNic4Xid5Rz[XSnIHL5JGlOSVBiYYPzZZktKEmFNUCgQUAxNjF2IN88UU4> MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV2MUO2Nkc,Ojl3NEGzOlI9N2F-
BL21(DE3) NYHrW2NKTnWwY4Tpc44h[XO|YYm= MUfJcohq[mm2aX;uJI9nKHB|OHHsdIhiKGGldHn2[UBnd3KvIHX4dJJme3OnZDDpckBGe2OqZYLpZ4hq[SClb3zpJGJNOjFqRFWzLUBk\WyuczDifUBJXFKIIHHzd4F6NCCLQ{WwJF0hOC5{NTFOwG0v M1;uUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUK4PFU5Lz5zOUmyPFg2QDxxYU6=
whole blood cells MmfzRY51cWmwZnzhcY1ifG:{eTDhd5NigQ>? M3OxO|QhcHK| MYDBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHnuJIh2dWGwIIfoc4xmKGKub3;kJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgWG5H[WyyaHGgdJJw\HWldHnvckBi\nSncjC0JIhzeyCkeTD0bY1mNXKnc3;seoVlKG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDBwNjFOwG0v MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd2OUK4Nkc,OjJ5NEmyPFI9N2F-
A673 NY\h[4U4eUiWUzDhd5NigQ>? MljndWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN? M{nrS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY Ml;VdWhVWyCjc4PhfS=> M4nEVZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy| NHS5[HA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD MlX0dWhVWyCjc4PhfS=> M3KxcpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? NYLpTlI5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH NY\qd2dbeUiWUzDhd5NigQ>? MlvVdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= MkfkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R) MVHxTHRUKGG|c3H5 MVHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN? NH76XpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 Mn[2dWhVWyCjc4PhfS=> NH7VXlhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz NGDMbI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC NGP1VG5yUFSVIHHzd4F6 NHXPUXJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> NUm4fW05RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Assay
Methods Test Index PMID
Western blot p-p38 / p38 ; mTOR / p-S6K / S6K / p-MK2 / MK2 / p-Hsp27 / Hsp27 ; p-p38 / γ-H2AX 23349819 26844273 27082306
In vivo BIRB 796 (30 mg/kg) inhibits 84% of TNF-α in LPS-stimulated mice and demonstrates efficacy in a mouse model of established collagen-induced arthritis. [1] BIRB 796 has good pharmacokinetic performance even after oral administration in mice. [2]

Protocol (from reference)

Animal Research:

[2]

  • Animal Models: Collagen-induced arthritis in female Balb/c mice
  • Dosages: 1 mg/kg (intravenous) or 10 mg/kg (oral)
  • Administration: Intravenous injection or by oral

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
5% DMSO+40%PEG300+5%Tween80 +50%H2O
For best results, use promptly after mixing.

5mg/mL

Chemical Information

Molecular Weight 527.66
Formula

C31H37N5O3

CAS No. 285983-48-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C4=CC=CC=C43)OCCN5CCOCC5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02211885 Completed Drug: 14C-BIRB 796 BS Healthy Boehringer Ingelheim October 2002 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Doramapimod (BIRB 796) | Doramapimod (BIRB 796) supplier | purchase Doramapimod (BIRB 796) | Doramapimod (BIRB 796) cost | Doramapimod (BIRB 796) manufacturer | order Doramapimod (BIRB 796) | Doramapimod (BIRB 796) distributor